David Vocadlo completed his PhD at the University of British Columbia in 2002. He was a postdoctoral fellow in the department of chemistry at the University of California at Berkeley. In 2004, he moved to Simon Fraser University (SFU), where he is now professor of chemistry and of molecular biology and biochemistry, co-director of the Center for High-Throughput Chemical Biology and Tier I Canada Research Chair in chemical biology. His research focuses on developing chemical biology tools to advance understanding the roles of glycoconjugates in health and disease. Dr. Vocadlo pioneered the creation and preclinical validation of glycosylation inhibitors for neurodegenerative diseases, a strategy now advanced into clinic trials. His research has been recognized with various awards including the EWR Steacie Memorial Fellowship, the Horace Isbell Award of the American Chemical Society and appointment as an inaugural member of the Royal Society of Canada, College of New Scholars.